Drug Profile


Alternative Names: Anti-CD4 monoclonal antibody IDEC-CE9.1; CE9.1; IDEC-CE9.1; PRIMATIZED anti-CD4 antibody IDEC-CE9.1; SB 210396

Latest Information Update: 15 May 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDEC Pharmaceuticals
  • Developer GlaxoSmithKline; IDEC Pharmaceuticals
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 15 May 2001 Discontinued-III for Asthma in USA (Unknown route)
  • 15 May 2001 Discontinued-III for Rheumatoid arthritis in USA (Infusion)
  • 15 May 2001 Discontinued-Preclinical for Rheumatoid arthritis in Japan (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top